CA974518A - Procedure for the manufacture of 1,3,5 trisubstituted adamantan compounds - Google Patents

Procedure for the manufacture of 1,3,5 trisubstituted adamantan compounds

Info

Publication number
CA974518A
CA974518A CA169,484A CA169484A CA974518A CA 974518 A CA974518 A CA 974518A CA 169484 A CA169484 A CA 169484A CA 974518 A CA974518 A CA 974518A
Authority
CA
Canada
Prior art keywords
adamantan
trisubstituted
compounds
procedure
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA169,484A
Other languages
English (en)
Other versions
CA169484S (en
Inventor
Dezso Peteri
Arthur Scherm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz and Co GmbH and Co KG
Original Assignee
Merz and Co GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2219256A external-priority patent/DE2219256C3/de
Priority claimed from DE2318461A external-priority patent/DE2318461A1/de
Application filed by Merz and Co GmbH and Co KG filed Critical Merz and Co GmbH and Co KG
Application granted granted Critical
Publication of CA974518A publication Critical patent/CA974518A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA169,484A 1972-04-20 1973-04-19 Procedure for the manufacture of 1,3,5 trisubstituted adamantan compounds Expired CA974518A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2219256A DE2219256C3 (de) 1972-04-20 1972-04-20 Oral und parenteral verabreichbares Arzneimittel zur Behandlung der Parkinson'sehen Krankheit
DE2318461A DE2318461A1 (de) 1973-04-12 1973-04-12 Verfahren zur herstellung von 1,3,5trisubstituierten adamanta-verbindungen

Publications (1)

Publication Number Publication Date
CA974518A true CA974518A (en) 1975-09-16

Family

ID=25763107

Family Applications (1)

Application Number Title Priority Date Filing Date
CA169,484A Expired CA974518A (en) 1972-04-20 1973-04-19 Procedure for the manufacture of 1,3,5 trisubstituted adamantan compounds

Country Status (8)

Country Link
US (1) US4122193A (es)
JP (1) JPS4918860A (es)
CA (1) CA974518A (es)
CH (1) CH603545A5 (es)
ES (1) ES413944A1 (es)
FR (1) FR2182998B1 (es)
GB (1) GB1393503A (es)
NL (1) NL7305644A (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
WO1992017168A1 (en) * 1991-04-04 1992-10-15 The Children's Medical Center Corporation Method of preventing nmda receptor-mediated neuronal damage
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
DE4225730C2 (de) * 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6294583B1 (en) * 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
NZ531785A (en) * 2001-08-20 2007-03-30 Maiken Nedergaard Treatment of glial tumors with ionotropic glutamate receptor antagonists
EP1298581A1 (fr) * 2001-09-27 2003-04-02 C.S.E.M. Centre Suisse D'electronique Et De Microtechnique Sa Procédé et dispositif pour calculer les valeurs des neurones d'un réseau neuronal
EP1556019A2 (en) 2002-10-24 2005-07-27 Merz Pharma GmbH & Co. KGaA Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
WO2005000216A2 (en) 2003-05-27 2005-01-06 Forest Laboratories, Inc. Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
CN1240668C (zh) * 2003-09-10 2006-02-08 上海医药工业研究院 一种新的盐酸美金刚制备方法
US20050113458A1 (en) * 2003-10-22 2005-05-26 Forest Laboratories, Inc. Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic a-beta peptides in amyloidopathies
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
WO2005069742A2 (en) * 2003-12-10 2005-08-04 Sun Pharmaceutical Industries Limited Crystal form ii of memantine hydrochloride
PL1703902T3 (pl) * 2004-01-05 2011-04-29 Merz Pharma Gmbh & Co Kgaa Memantyna do leczenia choroby Alzheimera o łagodnym do umiarkowanego stopniu zaawansowania
CN100363329C (zh) * 2004-01-09 2008-01-23 南京大学 合成美金刚胺盐酸盐的方法
US7456224B2 (en) * 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
CN101389315A (zh) 2004-06-17 2009-03-18 莫茨药物股份两合公司 美金刚口服剂型即释制剂
MXPA06014587A (es) * 2004-06-17 2007-04-27 Forest Laboratories Formulaciones de liberacion modificada de formulaciones de dosificacion oral de memantina.
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US20060079582A1 (en) * 2004-09-23 2006-04-13 Jeffrey Jonas Memantine for the treatment of childhood behavioral disorders
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
DE602006009619D1 (de) * 2005-01-11 2009-11-19 Teva Pharm Fine Chemicals Srl Verfahren zur herstellung von 1-amino-3,5-dimethyladamantan-hydrochlorid
ITMI20050833A1 (it) * 2005-05-10 2006-11-11 A M S A S P A Anonima Materie Sintetiche Affini Nuovo procedimento per la sintesi di aminoadamantani
EA013474B1 (ru) * 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
RU2008107336A (ru) 2005-07-27 2009-09-10 Дов Фармасьютикал, Инк. (Us) Новые 1-арил-з-азабицикло{3.1.0.} гексаны: получение и применение для лечения психоневрологических расстройств
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
PL1820792T3 (pl) * 2006-02-21 2012-06-29 Hexal Ag Sposób otrzymywania adamantanoamin
US20080033054A1 (en) * 2006-03-27 2008-02-07 Valeriano Merli Process for preparing memantine hydrochloride substantially free of impurities
ATE488520T1 (de) 2006-08-04 2010-12-15 Merz Pharma Gmbh & Co Kgaa Pyrazolopyrimidine, ein verfahren zu ihrer herstellung und ihre verwendung als medizin
EP1908748A1 (en) * 2006-10-05 2008-04-09 Krka Process for the preparation of memantine and its hydrochloric acid salt form
WO2008063847A2 (en) * 2006-11-03 2008-05-29 Forest Laboratories Holdings Limited Method for treating autism
CA2673481A1 (en) 2006-12-19 2008-06-26 University Of Virginia Patent Foundation Combined effects of topiramate and ondansetron on alcohol consumption
CN101622243B (zh) 2007-02-28 2013-12-04 旭化成制药株式会社 磺酰胺衍生物
WO2008153937A2 (en) 2007-06-06 2008-12-18 Dov Pharmaceutical, Inc. Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
GB0713930D0 (en) 2007-07-18 2007-08-29 Generics Uk Ltd Novel assay methods
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
EP2111858A1 (en) 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Novel treatment for alzheimer's disease
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
EP2138173A1 (en) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Pharmaceutical compositions comprising aminoadamantane derivatives
JP5195256B2 (ja) * 2008-10-10 2013-05-08 東ソー株式会社 アミノアダマンタン誘導体の製造方法
HRP20090186A2 (hr) 2009-03-31 2010-10-31 Institut Ruđer Bošković Adamantanski bisureidni derivati, metoda priprave i primjena u detekciji aniona
WO2010112221A1 (en) 2009-04-03 2010-10-07 Synthon B.V. Pharmaceutical compositions comprising memantine
CN102070463A (zh) * 2009-06-11 2011-05-25 辽宁利锋科技开发有限公司 具有金刚烷结构药物美金刚胺及其衍生物和类似物抗肿瘤新适应症的应用
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
CA2782556C (en) 2009-12-02 2018-03-27 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US20110251239A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
AR083475A1 (es) 2010-10-18 2013-02-27 Merz Pharma Gmbh & Co Kgaa Moduladores de receptores de glutamato metabotropicos
RU2013124827A (ru) 2010-10-29 2014-12-10 Мерц Фарма Гмбх Унд Ко. Кгаа Производные индола и способ их получения
CA2818025A1 (en) 2010-11-15 2012-05-24 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
WO2012085166A1 (en) 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
WO2012085167A1 (en) 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
CN102241678B (zh) 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
WO2012152854A1 (en) 2011-05-12 2012-11-15 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
WO2012172093A1 (en) 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dihydroindolizine derivate as metabotropic glutamate receptor modulators
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
CN103288650B (zh) * 2012-02-28 2015-09-30 广州白云山制药股份有限公司广州白云山制药总厂 一种盐酸1-氨基-3,5-二甲基金刚烷的制备方法
EP2650284A1 (en) 2012-04-10 2013-10-16 Merz Pharma GmbH & Co. KGaA Heterocyclic derivatives as metabotropic glutamate receptor modulators
RU2488388C1 (ru) 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US9566264B2 (en) 2013-07-01 2017-02-14 Euthymics Bioscience, Inc. Combinations and methods
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP6604957B2 (ja) 2014-02-04 2019-11-13 フォレスト・ラボラトリーズ・ホールディングス・リミテッド ドネペジル組成物及びアルツハイマー病を治療する方法
WO2016205739A1 (en) 2015-06-19 2016-12-22 Belew Mekonnen Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP6354701B2 (ja) * 2015-08-19 2018-07-11 大日本印刷株式会社 高純度メマンチン塩酸塩の製造法
WO2017223402A1 (en) 2016-06-23 2017-12-28 Corium International, Inc. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
MX2019001104A (es) 2016-07-27 2019-10-02 Corium Int Inc Sistemas de suministro transdermico de memantina.
CN109789134A (zh) 2016-07-27 2019-05-21 考里安国际公司 与口服递送药代动力学生物等效的透皮递送系统
KR102406536B1 (ko) 2016-07-27 2022-06-08 코리움, 인크. 도네페질 경피 전달 시스템
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10369187B2 (en) 2017-02-09 2019-08-06 Vanderbilt University Peptide regulators of JNK family kinases
JP2019094304A (ja) * 2017-11-27 2019-06-20 学校法人順天堂 オートファジー誘導剤
US11173132B2 (en) 2017-12-20 2021-11-16 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
CN112601749B (zh) 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
US11639328B2 (en) 2020-05-19 2023-05-02 Shandong Holly Pharmaceutical Co., Ltd. Method for preparing amantadine
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH76A (fr) * 1888-11-14 1889-01-09 Carnal Paul E Nouveau système de boîte de montre pouvant servir à volonté comme savonnette ou comme boîte à glace
US3391142A (en) * 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
FR1545327A (fr) * 1966-11-25 1968-11-08 Boehringer Sohn Ingelheim Nouveau procédé de fabrication de 2-hydroxy-3-aryloxy-propylamines secondaires
US3450761A (en) * 1967-03-30 1969-06-17 Sun Oil Co 1-aminoethyldimethyladamantane
US3929888A (en) * 1968-08-27 1975-12-30 Lilly Industries Ltd 2-Phenyl-adamantanealkylamine compounds and their salts
US3789073A (en) * 1970-04-22 1974-01-29 Squibb & Sons Inc Adamantylalkylaminoalkyl benzamides

Also Published As

Publication number Publication date
ES413944A1 (es) 1976-06-01
US4122193A (en) 1978-10-24
GB1393503A (en) 1975-05-07
JPS4918860A (es) 1974-02-19
NL7305644A (es) 1973-10-23
FR2182998A1 (es) 1973-12-14
CH603545A5 (es) 1978-08-31
FR2182998B1 (es) 1976-12-31

Similar Documents

Publication Publication Date Title
CA974518A (en) Procedure for the manufacture of 1,3,5 trisubstituted adamantan compounds
CA929516A (en) Process for the manufacture of 8-oxo-5-thia-1-azabicyclo-(4,2,0) oct-2-ene compounds
CA975490A (en) Process for the manufacture of polymeric compounds
CA1023766A (en) Process for the production of 3-halogen- and 3,5-dihalogen-phenols
GB1400485A (en) Process for the manufacture of 8-oxo-5-thia-1-azabicyclo- 4,2,0-oct-2-ene or -3-ene compounds
CA1023733A (en) Process for the manufacture of nuclear-sulphonated compounds
CA960698A (en) Process for the manufacture of 1,1,2,2-tetrahydro-perfluoro-alkanols
CA944135A (en) Apparatus for the manufacture of novel 1,2-dihydroquinolines
CA981699A (en) Process for the continuous manufacture of 3,4-dichlorobutene-1
CA981697A (en) Process for the manufacture of 3,4-dichlorobutene-1
CA1027973A (en) Process for the preparation of 1,2-dichloroethane
CA1006184A (en) Process for the disproportionation of diallylamines
CA936534A (en) Process for the manufacture of 5,6-benzquinaldine
CA981698A (en) Process for the manufacture of 3,4-dichlorobutene-1
CA967975A (en) Process for the manufacture of 2,5-diacylamino-1,4-benzoquinones
CA966506A (en) Process for the isomerization of 5-vinylbicyclo(2.2.1)hept-2-enes
CA895304A (en) Process for the manufacture of 1,2-dihydrobenzodiazepines
CA1022170A (en) Process for the manufacture of new triazolo-benzodiazepines
CA846171A (en) Process for the manufacture of 1,2-dihydrobenzodiazepine
CA873875A (en) Process for the manufacture of 1,4-dihalogenanthraquinones
CA851722A (en) Process for the production of 1,3-n-s-heterocyclic compounds
CA892029A (en) Process for the manufacture of a 1,2-dihydrobenzodiazepine
CA904297A (en) Process for preparing 1,2,3,4-tetrahydro-7-halo-6-sulfamyl-4-quinazolinone and the compound thereby obtained
CA802217A (en) Process for the preparation of new 1,4-benzdioxan compounds
CA894243A (en) Process for the preparation of 9-pyridylalkyl-1,2,8,9-tetraazaphenale nes